Pancreatic Cancer Research

ResearcherJikei University School of MedicineNo recent work listed

Takashi Horiuchi

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: none · 2020: none · 2021: 4 papers · 2022: 1 paper

Papers 14

  1. Inhibition of lysosomal acid β-glucosidase induces cell apoptosis via impairing mitochondrial clearance in pancreatic cancer. Co-author DOI 10.1093/carcin/bgac060↗
  2. Thrombomodulin expression impacts the recurrence and long-term survival in pancreatic cancer. Co-author DOI 10.1002/ags3.12447↗
  3. Practical significance of pancreatectomy with lymphadenectomy around the superior mesenteric artery for pancreatic cancer: comparison of prognosis after adjust… Co-author DOI 10.1007/s00423-021-02166-0↗
  4. Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer. Co-author DOI 10.1111/cas.14921↗
  5. Inhibition of acid ceramidase elicits mitochondrial dysfunction and oxidative stress in pancreatic cancer cells. Co-author DOI 10.1111/cas.15123↗
  6. Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Co-author DOI 10.18632/oncotarget.24577↗
  7. Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo. Co-author DOI 10.18632/oncotarget.24608↗
  8. C-Reactive Protein-based Prognostic Measures Are Superior at Predicting Survival Compared with Peripheral Blood Cell Count-based Ones in Patients After Curativ… Co-author DOI 10.21873/anticanres.13013↗
  9. Recombinant thrombomodulin suppresses tumor growth of pancreatic cancer by blocking thrombin-induced PAR1 and NF-κB activation. Co-author DOI 10.1016/j.surg.2016.12.008↗
  10. Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection. Co-author DOI 10.21873/anticanres.11378↗
  11. The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection. Co-author DOI 10.1007/s00268-016-3491-4↗
  12. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer. Co-author DOI 10.1016/j.jss.2016.06.047↗
  13. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Co-author DOI 10.1016/j.surg.2015.03.043↗
  14. Negative Impact of Preoperative Endoscopic Biliary Drainage on Prognosis of Pancreatic Ductal Adenocarcinoma After Pancreaticoduodenectomy. Co-author PMID 26254410↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshihiro Shirai · 14 shared papers, 2015–2022 · strength 1.23
  2. Koichiro Haruki · 10 shared papers, 2015–2022 · strength 0.78
  3. Katsuhiko K. Yanaga · 10 shared papers, 2015–2021 · strength 0.73
  4. Ryoga Hamura · 6 shared papers, 2018–2022 · strength 0.71
  5. Kenei Furukawa · 7 shared papers, 2015–2022 · strength 0.64
  6. Toru Ikegami · 5 shared papers, 2021–2022 · strength 0.63
  7. Hiroaki Shiba · 9 shared papers, 2015–2018 · strength 0.60
  8. Tomohiko Taniai · 4 shared papers, 2021–2022 · strength 0.50
  9. Nobuhiro Saito · 6 shared papers, 2016–2021 · strength 0.49
  10. Tadashi Uwagawa · 5 shared papers, 2016–2018 · strength 0.36
  11. Takeshi Gocho · 3 shared papers, 2018–2021 · strength 0.34
  12. Yuki Fujiwara · 5 shared papers, 2015–2018 · strength 0.31
  13. Tadashi Uwagawa · 2 shared papers, 2021–2022 · strength 0.25
  14. Mitsuru Yanagaki · 2 shared papers, 2021–2022 · strength 0.25
  15. Hiroshi Sugano · 2 shared papers, 2018–2021 · strength 0.21
  16. Hironori Shiozaki · 1 shared paper, 2021 · strength 0.13
  17. Shinji Onda · 1 shared paper, 2021 · strength 0.13
  18. Taro Sakamoto · 2 shared papers, 2015–2017 · strength 0.12
  19. Shinji Tanaka · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.